Loading
MAVORIC showed that mogamulizumab, an antibody that clears the malignant T cells that carry the CCR4 protein, kept cutaneous T-cell lymphoma under control for longer than the standard tablet vorinostat, and did especially well in the blood-involved Sezary form, which led to its approval.
MAVORIC was an open-label phase 3 trial in patients with mycosis fungoides or Sezary syndrome who had failed at least one systemic therapy. Patients were randomised to mogamulizumab, an afucosylated antibody against CCR4 that depletes malignant T cells, or to vorinostat, an approved histone deacetylase inhibitor; patients progressing on vorinostat could cross over.
Mogamulizumab significantly prolonged progression-free survival, the primary endpoint, with higher response rates, and the benefit was greatest in patients with blood involvement, the hallmark of Sezary syndrome. It was the first randomised trial in cutaneous T-cell lymphoma to compare two systemic drugs head to head and led to approval of mogamulizumab in the United States in August 2018.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.